Bayer′s Healthcare Sales Declined In 2004 | Business| Economy and finance news from a German perspective | DW | 11.02.2005
  1. Inhalt
  2. Navigation
  3. Weitere Inhalte
  4. Metanavigation
  5. Suche
  6. Choose from 30 Languages


Bayer's Healthcare Sales Declined In 2004

The German pharmaceuticals and chemicals giant Bayer sustained a decline in sales in its troubled healthcare division last year, while revenues in its two other divisions, industrial chemicals and crop protection, rose, a company spokesman said Friday. Bayer, maker of Aspirin painkiller, booked sales of around €8.5 billion ($10.9 billion) in its healthcare division last year. Thus, sales are down from €8.9 billion a year earlier, even though Bayer sold its blood plasma products activities. By contrast, revenues in the chemicals division, MaterialScience, rose to €8.5 billion from €7.5 billion. And in the agrochemicals division, CropScience, turnover rose to an estimated €6 billion from €5.8 billion. Bayer, which is scheduled to publish 2004 earnings in mid-March, estimated that fourth-quarter earnings were up on year-earlier levels, the spokesman added.

DW recommends